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n Generalized anxiety disorder (GAD) is characterized by excessive, pervasive and uncontrollable worry. Associated symptoms include irritability, restlessness and concentration problems. Somatic symptoms of GAD include muscle tension, sweating, dry mouth, nausea and diarrhea.
1 GAD is a chronic and recurrent disorder with a low rate of remission.
2 GAD has a considerable impact on quality of life and is associated with increased reliance in public assistance, impaired social life and low ratings of life satisfaction. 3 The current and lifetime prevalence of GAD have been estimated to be 1.6% and 5.1% respectively. 4 The lifetime prevalence of psychiatric comorbidities in GAD patients can reach over 90%. 4 The most common co-morbidities are major depressive disorder (62%) and dysthymia (39%). 5 Comorbidities such as major depression do not appear to change the course of GAD. 6 Benzodiazepines and non benzodiazepine anxiolytics such as buspirone have been the mainstay for the treatment of GAD in the past. 7 As GAD tends to be a chronic condition, longterm pharmacological treatment is often necessary. This raises concern about the use of benzodiazepines, since these compounds may be associated with risks of abuse and dependence. Buspirone is devoid of the dependence risks associated with benzodiazepines, however it has a more limited spectrum of efficacy and delayed onset of action when compared to other treatments.
A variety of psychotherapeutic approaches have been used to treat GAD. To date, the most consistent results on the psychotherapy of GAD comes from the cognitive-behavioral therapy (CBT) approach. Results from well-conducted trials suggest that CBT can produce clinically relevant and long term therapeutic improvements as compared with controls. Psychotherapeutic approaches also seem to be well tolerated by patients and the dropout rates in clinical trials are low.
8
There are also data supporting the notion that psychotherapy may have an additional impact in the comorbid conditions associated to GAD. 8 The first trial assessing the effect of antidepressants in GAD, diagnosed according to DSM-III criteria, was conducted by Hoehn-Saric et al. 9 These authors compared alprazolam and imipramine in a group of 52 GAD patients. They showed that both drugs were effective in treating GAD. However, imipramine was more effective in attenuating psychological symptoms such as dysphoria and anticipatory negative thinking, whereas alprazolam was more effective in somatic symptoms and in the hyperarousal associated with GAD. The same trend was detected by Rickels et al 10 in a comparison between imipramine, trazodone, diazepam and placebo. Rickels et al 10 showed that from week 3 through week 8, trazodone achieved similar anxiolytic efficacy to diazepam; the effect of imipramine was found to be somewhat better, and psychological symptoms such as apprehension and worry responded better to the antidepressants than to anxiolytics. A study by Rocca and associates, 11 within a sample of DSM-IV diagnosed GAD patients, supported the theory that antidepressants affect predominantly psychological symptoms whereas benzodiazepine affect predominantly somatic symptoms in GAD. A comparison between antidepressants and non benzodiazepine anxiolytics is available only for venlafaxine and buspirone. 12 This study included 365 patients and showed that venlafaxine and buspirone were superior to placebo in the majority of outcomes considered. There is also evidence that the management of benzodiazepine discontinuation in GAD patients can be facilitated by co-prescribing imipramine but not buspirone. 13 In the light of the data presented, there are reasons to believe that antidepressants may offer a valuable alternative in the treatment of GAD patients. In the present review, randomized controlled trials (RCT) data on the use of antidepressants for treating GAD were assessed.
Aims of the study: To assess the efficacy and acceptability of antidepressants for treating generalized anxiety disorder.
Methods

Methods Methods
Methods Methods 1. T 1. T 1. T 1. T 1. Types of studies ypes of studies ypes of studies ypes of studies ypes of studies All relevant randomized controlled trials comparing antidepressants to placebo or to another active pharmacological treatment (see Selection of trials).
2. T 2. T 2. T 2. T 2. Types of par ypes of par ypes of par ypes of par ypes of participants ticipants ticipants ticipants ticipants People with a diagnosis of generalized anxiety disorder irrespective of gender, race, age or nationality.
Exclusion criteria: patients with generalized anxiety disorder and another Axis I co-morbidity. The terms used in the search were: anxiety or anxiety disorder and pharmacotherapy-5ht or pharmacotherapy-ad or pharmacotherapy-maoi or pharmacotherapy-nari or pharmacotherapy-rima or pharmacotherapy-r-ssri or pharmacotherapy-r-tca or pharmacotherapy-snri or pharmacotherapy-ssri or pharmacotherapy-tca.
2) Conference abstracts were searched.
3) Personal communication: in order to ensure that as many RCTs as possible would be identified, the authors of included studies were consulted to find out if they know of any published or unpublished RCTs/ CCTs on pharmacological treatment of GAD which had not yet been identified. A list of all RCTs identified from other sources was sent to the authors. 4) Attempts were made to obtain unpublished trials from pharmaceuticalcompanies.
5) Book chapters on treatment of GAD were reviewed.
6. Selection of trials 6. Selection of trials 6. Selection of trials 6. Selection of trials 6. Selection of trials One reviewer screened the abstracts of all publications that were obtained by the search strategy. A distinction was made between:
1) Eligible studies, in which antidepressants were compared to placebo or another drug;
2) Studies without any control element; studies of general treatment for GAD rather than pharmacological; studies of drug treatments other than antidepressants.
For abstracts where the authors found any indication of a clinical trial, the full article was obtained and inspected to assess its relevance to this review.
7. Quality assessment 7. Quality assessment 7. Quality assessment 7. Quality assessment 7. Quality assessment In order to ensure that variation was not caused by systematic errors in the design of a study, the methodological quality of the selected trials was assessed by two independent reviewers. The methodological quality was assessed using the criteria described in the Cochrane Handbook . It is based on the evidence of a strong relationship between the potential for bias in the results and the allocation concealment and is defined as below:
1) Low risk of bias (adequate allocation concealment).
2) Moderate risk of bias (unclear method of allocation concealment).
3) High risk of bias (inadequate allocation concealment). For the purpose of the analysis in this review, trials were included if they met criteria A or B as described in the Cochrane Handbook.
8. Data management 8. Data management 8. Data management 8. Data management 8. Data management Data were independently extracted by two reviewers. Any disagreement was discussed with a third reviewer, decisions were documented and, where necessary, the study authors contacted to resolve the issue. All exclusions/dropouts were identified. If no information was available (either from the report or the authors) it was assumed that dropouts were due to side effects/treatment failure. 9. Analysis 9. Analysis 9. Analysis 9. Analysis 9. Analysis In the statistical analysis, the relative risk (RR) and 95% confidence interval for dichotomous variables were calculated using the random effects model, as it takes into account of any between study differences (even if there is no statistically significant heterogeneity) and gives the same result as the fixed effects model when there is no between-study variance. Review Manager Software 4.1 was used to analyse the results. In the efficacy analysis, the number needed to treat (NNT) was also calculated, using 95% confidence intervals. The NNT is defined as the inverse of differences of risk between groups. The NNT expresses the number of patients that have to be treated in order to achieve one additional response, when compared to the control group. R e s u l t s R e s u l t s R e s u l t s R e s u l t s R e s u l t s 15 Other included studies were used in the analysis of number of dropouts and specific side effects.
In general, short-term treatment response was more likely in patients receiving antidepressants than placebo. One study, 10 compared four treatments (imipramine, trazodone, diazepam and placebo). As imipramine was considered a reference antidepressant, we used the 'imipramine vs placebo' comparison rather than 'trazodone vs placebo'. Considering all trials, the pooled RR for non treatment response was 0.70 (95% confidence interval (CI) 0.62 to 0.79), favouring antidepressant treatment. The calculated NNT was 5.5 (95% CI 4.1 to 8.4).
-Imipramine: 10 The calculated RR was 0.67 (95% CI 0.50 to 0.91) and the NNT was 4.0 (95% CI 2.4 to 13.7).
-Venlafaxine: 12,14 The calculated RR for non treatment response was 0.68 (95% CI 0.46 to 0.99), and the calculated NNT was 5.0 (95% CI 3.58 to 8.62) . The studies carried out by Rickels 2000 13 and Allgulander 2001 16 could not be used for the efficacy analysis, as data could not be extracted as reported.
-Paroxetine: 15 The calculated RR was 0.72 (95% CI 0.56 to 0.92), and the calculated NNT was 6.72 (95% CI 3.9 to 24.7).
-Paroxetine vs imipramine: 17 The calculated RR was 1.73 (95% CI 0.31 to 9.57).
Sertraline vs placebo in children and adolescents: -Sertraline: 18 This study was not included in the meta analysis because it studied children and adolescents. The results obtained in this small trial (N = 22) were very compelling, showing a calculated NNT of 1.22 (95% CI 0.90 to -1.7).
3. Acceptability 3. Acceptability 3. Acceptability 3. Acceptability 3. Acceptability 1) Dropouts (Table 3 ) No significant differences were found between antidepressants and placebo. The RR for dropout for any antidepressant was 0.95 (95% CI 0.84 to 1.09). Similarly, when individual antidepressants were considered, no differences were found between individual treatments and the placebo group:
- 2) Common drug specific side effects: Overall, side effects were more common in the drug treated than in the placebo treated groups. Data for more than one trial were available only for venlafaxine:
-Venlafaxine: 12,14 those taking venlafaxine were more likely to report nausea, dry mouth, insomnia, constipation, somnolence, anorexia, sexual dysfunction and flatulence. The present review showed the efficacy of antidepressants in the treatment of GAD. These results were obtained when drugs with differential profiles such as imipramine and venlafaxine were compared to placebo. The calculated NNT for these antidepressants as a group, was 5.54. This means that about 6 patients have to be treated to cause one additional clinical improvement.
Imipramine showed a smaller NNT (4.07, 95% CI 2.39 to 13.74) than venlafaxine = 5.06 (95% CI 3.6 to 8.6) and paroxetine = 6.7 (95% CI 3.9 or 24.7). However, this does not allow for the conclusion that the effect size of imipramine is larger. Only one study compared an SSRI (paroxetine) to imipramine, and similar results were found for the efficacy assessment and acceptability. The available evidence clearly suggests that antidepressants are better than placebo. The idea that antidepressants may improve both symptoms of depression and anxiety is not a new one. However, this review was conducted using studies which included patients with GAD without concurrent major depression or other Axis I comorbidities. This allows to conclude that the anxiolytic effect of antidepressants in GAD is independent from its effect on major depression and dysthymia.
Only one study assessed the use of antidepressants among children and adolescents. This study included a small sample of patients (N = 22) and, therefore, results should be viewed with caution. However, the effect size obtained was very robust, which suggests that younger patients may have a more favourable response than adults. There is no evidence that one antidepressant is superior to any other. Additional clinical trials comparing different antidepressants are needed to address this issue.
2. Acceptability 2. Acceptability 2. Acceptability 2. Acceptability 2. Acceptability Overall, the number of patients dropping out of studies was similar in the antidepressant and placebo groups. Newer antidepressants such as venlafaxine and paroxetine usually have a better acceptability profile than tricyclics. However, there was no difference between the tricyclic imipramine and the new antidepressants (venlafaxine and paroxetine) in terms of dropouts. Again, a direct comparison between venlafaxine and imipramine in terms of acceptability is lacking. Some insight into this question can be drawn from the study conducted by Rocca 1997, 17 which allowed a direct comparison between imipramine and the selective serotonin reuptake inhibitor (SSRI) paroxetine. In the latter study, similar rates of dropouts were reported, adding to the notion that acceptability may not vary as much as one might expect when newer, and supposedly better tolerated drugs, are compared to the tricyclics. The study conducted by Rocca 1997 17 cannot be R e f e r e n c e s R e f e r e n c e s R e f e r e n c e s R e f e r e n c e s R e f e r e n c e s 
